Hereditary and sporadic renal cell carcinomas (RCCs) are often associated with Von Hippel-Lindau (VHL)-gene inactivation. Patients with VHL disease have an increased risk of RCC, leading to bilateral nephrectomy and dialysis. In patients with advanced RCC, no standard second-lines are available after progression to immune checkpoint inhibitors (ICIs), and new agents are required to manage progression. HIFs have emerged as a promising target for metastatic RCC patients who have progressed to ICI-based combinations, as well as for those with RCC and VHL syndrome where the goal is to delay surgery and/or and preserve kidney function and avoid dialysis. This review describes the available evidence supporting the use of the small-molecule HIF-2 alpha inhibitor, belzutifan (MK-6482), as well as other new anti-HIF molecules that have demonstrated significant efficacy in VHL disease-related RCCs as well as for sporadic RCC that has progressed after the use of ICI-based combinations.

Iacovelli, R., Arduini, D., Ciccarese, C., Pierconti, F., Strusi, A., Piro, G., Carbone, C., Foschi, N., Daniele, G., Tortora, G., Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers, <<CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY>>, 2022; 176 (Aug): N/A-N/A. [doi:10.1016/j.critrevonc.2022.103750] [https://hdl.handle.net/10807/274140]

Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers

Iacovelli, Roberto;Arduini, Daniela;Ciccarese, Chiara;Pierconti, Francesco;Strusi, Alessandro;Carbone, Carmine;Foschi, Nazario;Daniele, Gennaro;Tortora, Giampaolo
2022

Abstract

Hereditary and sporadic renal cell carcinomas (RCCs) are often associated with Von Hippel-Lindau (VHL)-gene inactivation. Patients with VHL disease have an increased risk of RCC, leading to bilateral nephrectomy and dialysis. In patients with advanced RCC, no standard second-lines are available after progression to immune checkpoint inhibitors (ICIs), and new agents are required to manage progression. HIFs have emerged as a promising target for metastatic RCC patients who have progressed to ICI-based combinations, as well as for those with RCC and VHL syndrome where the goal is to delay surgery and/or and preserve kidney function and avoid dialysis. This review describes the available evidence supporting the use of the small-molecule HIF-2 alpha inhibitor, belzutifan (MK-6482), as well as other new anti-HIF molecules that have demonstrated significant efficacy in VHL disease-related RCCs as well as for sporadic RCC that has progressed after the use of ICI-based combinations.
2022
Inglese
Iacovelli, R., Arduini, D., Ciccarese, C., Pierconti, F., Strusi, A., Piro, G., Carbone, C., Foschi, N., Daniele, G., Tortora, G., Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers, <<CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY>>, 2022; 176 (Aug): N/A-N/A. [doi:10.1016/j.critrevonc.2022.103750] [https://hdl.handle.net/10807/274140]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/274140
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact